- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02398708
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
Comparison of the Fecal Microbiome, Peripheral Inflammatory Markers, and Symptoms in Individuals Discordant for GVHD After Allogeneic Hematopoietic Stem Cell Transplant
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will recruit 40 (20 with cGVHD and 20 without cGVHD) adults from the Bone Marrow Transplant Program at University of Florida Health Shands Cancer Hospital. After signing informed consent, participants will fill out questionnaires and have a blood sample collected from a vein in the arm. Participants will be given a stool collection kit with instruction and will return the sample via the mail. Data will be collected and securely stored in a system used by the cancer center for research. Descriptive statistics will be used to report individual, clinical factors, and symptoms.
Knowledge gained from this study will provide preliminary data for future longitudinal studies to examine biological pathways for the development, severity and/or duration of cGVHD and symptom outcomes in individuals following allo-HSCT impacting quality of life.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- UF Health Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Group 1: Adults (> 18 years of age) within 3 months to 3 years of receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) diagnosed with cGVHD;
- Group 2: Adults (> 18 years of age) within 3 months to 3 years of receiving allo-HSCT without a diagnosis of cGVHD; and
- All participants must be able and willing to complete paper and pencil questionnaires, provide a blood and stool sample, and be able to give informed consent.
Exclusion Criteria:
- Diagnosed with a significant secondary inflammatory disease such as multiple sclerosis, Crohn's disease, rheumatoid arthritis or secondary cancer;
- History of a major psychological disorder requiring psychotropic medications or initiation of antidepressants within 30 days of enrollment;
- Incarcerated or pregnant; or
- Any other condition that in the opinion of the principal investigator (PI) may compromise study participation will not be eligible for participation in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chronic Graft-Versus-Host Disease
This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
|
Both groups will have questionnaires collected and compared.
Both groups will have a blood sample collected and compared.
Both groups will have a stool sample collected and compared.
Both groups will have clinical data collected and compared.
|
No Chronic Graft-Versus-Host Disease
This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
|
Both groups will have questionnaires collected and compared.
Both groups will have a blood sample collected and compared.
Both groups will have a stool sample collected and compared.
Both groups will have clinical data collected and compared.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma levels of inflammatory markers (cytokines and CRP) of individuals post allogeneic HSCT
Time Frame: Day 1
|
Cytokines will be analyzed using a multiplex assay by Millipore Company.
Compared to the traditional enzyme-linked immunosorbant assays (ELISA), the multiplex is comparable and more sensitive to lower concentration levels of cytokines than the ELISA.
One laser identifies a specific bead and another laser identifies the reported antibody associated with the bead-bound cytokine.
One hundred beads for each of the 17 cytokines in every sample are assayed and a mean cytokine binding for the sample is determined.
The manufacturer reports that the assay accurately measures cytokine values in a range of 1-2500pg/ml.
Serum CRP will be measured using the ALPCO's (American Laboratory Products Company) high-sensitivity CRP assay which uses latex particle enhanced immunoturbidimetry for quantitative CRP determination.
|
Day 1
|
Diversity and levels of fecal microbes of individuals post allogeneic HSCT
Time Frame: Day 1
|
Fecal microbial DNA will be extracted from between 50-200 mg of fecal material.
The 16S ribosomal gene (V4 region) of each sample will be amplified using a barcoding system to allow multiplexing with the Illumina MiSeq system.
We will use UNIFRAC algorithm to evaluate the null hypothesis that the structure of the microbial community is insensitive to cGVHD and symptoms of cGVHD.
Differences in taxa are implicated by our high throughput sequencing methods will be confirmed by other techniques including culturing (where appropriate) and qPCR with taxa-specific primers.
|
Day 1
|
Behavioral responses (symptoms) of individuals post allogeneic HSCT
Time Frame: Day 1
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Promoting Lifestyle Profile II (HPLPII)
Time Frame: Day 1
|
The Health Promoting Lifestyle Profile II (HPLPII) will be used to identify lifestyle choices that may affect relationships and differences between groups.
HPLPII measures health promoting behaviors across several dimensions with subscales of health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations and stress management.
This is a 52-item summated behavior rating scale using a 4-point response format to measure the frequency of self-reported health-promoting behaviors.
It is a well validated toll and takes approximately 10 minutes to complete.
|
Day 1
|
Perceived Stress Scale (PSS)
Time Frame: Day 1
|
The Perceived Stress Scale (PSS) will be used to measure individual's level of perceived stress which may affect levels of inflammation.
This is a short 10 question form rating individuals ability to tolerate change and unpredictable situations.
This is the most widely used measure of individual's perceived stress and is well validated.
It takes approximately 5 minutes to complete.
|
Day 1
|
Brief Pain Inventory (BPI)
Time Frame: Day 1
|
Pain will be assessed using the Brief Pain Inventory (BPI).
The BPI was created to evaluate two dimensions of pain: 1) the severity and 2) the interference.
This tool is well validated with Cronbach's alpha .80-.87 pain severity and .89-.92 for interference.22
The BPI consists of a body diagram to indicate location of pain and a general question asking if pain is present.
Four items assess pain intensity or severity and seven item s assess pain interference.
Both use an eleven point scale ranging from 0 (no pain or interference) to 10 (worst pain or interference).
This instrument takes approximate five minutes to complete.
|
Day 1
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Day 1
|
Depressive symptoms will be assessed using the subscale for depression from the Hospital Anxiety and Depression Scale (HADS).
23This instrument is used to assess the presence and severity of anxiety and depressive symptoms over a seven day period.
The depression subscale is comprised of seven items using a four point scale ranging from 0 (least severe) to 3 (most severe).
Cronbach's alpha has been found to be high (.82-.90) for the HADS depression subscale.
|
Day 1
|
Brief Fatigue Inventory (BFI)
Time Frame: Day 1
|
Fatigue will be assessed using the Brief Fatigue Inventory (BFI).
The BFI is a nine item, eleven point scale that assesses physical, affective, cognitive and social domains in a two dimensions, fatigue intensity and interference.
Severity scores are as follows: 1) mild (1-3), 2) moderate (4-6) and 3) severe (7-10).
This tool is well establish and validated.
The Cronbach's alpha ranged from .95-.96 for individual items and an internal consistency of .96
overall.
The questionnaire takes approximately five minutes to complete and a global score can be ascertained by averaging the total score.
|
Day 1
|
Lee Symptom Bother Scale
Time Frame: Day 1
|
The Lee Symptom Bother Scale is a multi-symptom scale that measures the severity of symptoms as described as how much a symptom bothers the patient.
25There are seven domains assessed: 1) skin, 2) eye, 3) mouth, 4) lung function, 5) nutrition, 6) psychosocial status, and 7) energy.
All areas are rated using a 5 point Likert type scale where 0 indicates "Not at all" and 4 indicates "Extremely" bothered.
A summary score is created by taking the mean of all items and linearly transforming that value to a 0-100 scale.
The Chronbach's α is between .79 and .90.
The test-retest reliability for all subscales is .74-.93 except psychosocial is .55 and lung is .28.
The scale has good convergent validity.
|
Day 1
|
Memorial Symptom Assessment Scale (MSAS-SF)
Time Frame: Day 1
|
To comprehensively explore symptoms, the Memorial Symptom Assessment Scale (MSAS-SF) will be used to measure multiple dimensions (frequency, severity, and distress) of 32 common cancer symptoms.
The Cronbach alpha for the MSAS-SF subscales ranged from .76-.86 and the test-retest correlation coefficients ranged from .86-.94 at one day and one week respectively.
The total time to complete this form is approximately 10 minutes.
This form allows for patients to identify and quantify "other" symptoms.
|
Day 1
|
Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT)
Time Frame: Day 1
|
Health related quality of life (HRQOL) will be measured using the Functional Assessment of Cancer Therapy- Bone Marrow Transplantation (FACT-BMT).
This is a well validated HRQOL measure.
This is a 27-item questionnaire asking questions across four domains: physical well-being, social well-being, emotional well-being and functional well-being.
This measure takes about 10 minutes to complete.
|
Day 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Debra Lynch Kelly, PhD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201400992
- UF-BMT-cGVHD-101 (Other Identifier: University of Florida Protocol ID)
- ID00023244 (Other Grant/Funding Number: American Cancer Society)
- OCR14208 (Other Identifier: OnCore)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic Stem Cell Transplantation
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCCompletedHematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Hematopoietic | Transplantation, Hematopoietic Stem CellUnited States
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
National Cancer Institute (NCI)RecruitingHematopoietic Stem Cell TransplantationUnited States
-
Seoul National University HospitalNational Institute of Food and Drug Safety Evaluation (Republic of Korea)RecruitingHematopoietic Stem Cell TransplantationKorea, Republic of
-
University of Michigan Rogel Cancer CenterRecruitingHematopoietic Stem Cell TransplantationUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedHematopoietic Stem Cell TransplantationBrazil
-
Seoul National University HospitalCompletedHematopoietic Stem Cell TransplantationKorea, Republic of
-
University of OsloRecruitingHematopoietic Stem Cell TransplantationNorway
Clinical Trials on Questionnaires
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Direction Centrale du Service de Santé des ArméesCompleted
-
Sun Yat-sen UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care SyndromeFrance
-
University Hospital, GrenobleUniversity Grenoble AlpsNot yet recruitingChildhood Cancer | Adapted Physical ActivityFrance
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The University of Hong KongCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedBreast Cancer | MetastasisUnited States
-
Cliniques universitaires Saint-Luc- Université...Fonds National de la Recherche ScientifiqueNot yet recruitingAlcohol Use Disorder